Literature DB >> 20110379

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.

Natalia Polanco1, Elena Gutiérrez, Adelardo Covarsí, Francisco Ariza, Agustín Carreño, Ana Vigil, José Baltar, Gema Fernández-Fresnedo, Carmen Martín, Salvador Pons, Dolores Lorenzo, Carmen Bernis, Pilar Arrizabalaga, Gema Fernández-Juárez, Vicente Barrio, Milagros Sierra, Ines Castellanos, Mario Espinosa, Francisco Rivera, Aniana Oliet, Francisco Fernández-Vega, Manuel Praga.   

Abstract

Spontaneous remission is a well known characteristic of idiopathic membranous nephropathy, but contemporary studies describing predictors of remission and long-term outcomes are lacking. We conducted a retrospective, multicenter cohort study of 328 patients with nephrotic syndrome resulting from idiopathic membranous nephropathy that initially received conservative therapy. Spontaneous remission occurred in 104 (32%) patients: proteinuria progressively declined after diagnosis until remission of disease at 14.7 +/- 11.4 months. Although spontaneous remission was more frequent with lower levels of baseline proteinuria, it also frequently occurred in patients with massive proteinuria: 26% among those with baseline proteinuria 8 to 12 g/24 h and 22% among those with proteinuria >12 g/24 h. Baseline serum creatinine and proteinuria, treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, and a >50% decline of proteinuria from baseline during the first year of follow-up were significant independent predictors for spontaneous remission. Only six patients (5.7%) experienced a relapse of nephrotic syndrome. The incidence of death and ESRD were significantly lower among patients with spontaneous remission. In conclusion, spontaneous remission is common among patients with nephrotic syndrome resulting from membranous nephropathy and carries a favorable long-term outcome with a low incidence of relapse. A decrease in proteinuria >50% from baseline during the first year predicts spontaneous remission.

Entities:  

Mesh:

Year:  2010        PMID: 20110379      PMCID: PMC2844306          DOI: 10.1681/ASN.2009080861

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  30 in total

Review 1.  Idiopathic membranous glomerulonephritis.

Authors:  D C Cattran
Journal:  Kidney Int       Date:  2001-05       Impact factor: 10.612

2.  Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.

Authors:  Alvaro Torres; Beatriz Domínguez-Gil; Agustín Carreño; Eduardo Hernández; Enrique Morales; Julian Segura; Ester González; Manuel Praga
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

3.  Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.

Authors:  D C Cattran; G B Appel; L A Hebert; L G Hunsicker; M A Pohl; W E Hoy; D R Maxwell; C L Kunis
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

4.  The natural history of the non-nephrotic membranous nephropathy patient.

Authors:  Michelle A Hladunewich; Stephan Troyanov; Jennifer Calafati; Daniel C Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-06       Impact factor: 8.237

5.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Authors:  T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

6.  Idiopathic membranous nephropathy: definition and relevance of a partial remission.

Authors:  Stéphan Troyanov; Catherine A Wall; Judith A Miller; James W Scholey; Daniel C Cattran
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

7.  Clinicopathologic correlations of renal pathology in Spain.

Authors:  Francisco Rivera; Juan Manuel López-Gómez; Rafael Pérez-García
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

8.  Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.

Authors:  Peggy W G du Buf-Vereijken; Amanda J W Branten; Jack F M Wetzels
Journal:  Nephrol Dial Transplant       Date:  2004-02-19       Impact factor: 5.992

9.  Rituximab for idiopathic membranous nephropathy.

Authors:  Giuseppe Remuzzi; Carlos Chiurchiu; Mauro Abbate; Verusca Brusegan; Mario Bontempelli; Piero Ruggenenti
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

10.  The natural history of membranous nephropathy in the West of Scotland.

Authors:  R MacTier; J M Boulton Jones; C D Payton; A McLay
Journal:  Q J Med       Date:  1986-08
View more
  121 in total

1.  Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR).

Authors:  Hitoshi Yokoyama; Takashi Taguchi; Hitoshi Sugiyama; Hiroshi Sato
Journal:  Clin Exp Nephrol       Date:  2012-02-23       Impact factor: 2.801

Review 2.  Idiopathic membranous nephropathy: an autoimmune disease.

Authors:  Sudesh P Makker; Alfonso Tramontano
Journal:  Semin Nephrol       Date:  2011-07       Impact factor: 5.299

3.  Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy.

Authors:  Jan A J G van den Brand; Peter R van Dijk; Julia M Hofstra; Jack F M Wetzels
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

4.  American Society of Nephrology quiz and questionnaire 2014: glomerular diseases.

Authors:  Andrew S Bomback; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-09       Impact factor: 8.237

5.  Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated.

Authors:  Chadwick E Barnes; William A Wilmer; Raul A Hernandez; Christopher Valentine; Leena S Hiremath; Tibor Nadasdy; Anjali A Satoskar; Rose L Shim; Brad H Rovin; Lee A Hebert
Journal:  Nephron Clin Pract       Date:  2011-07-08

6.  Proteinuria in a patient with Graves' disease: Questions.

Authors:  Aydilek Dagdeviren Cakir; Nur Canpolat; Seha Saygili; Isin Kilicaslan; Hande Turan; Oya Ercan; Olcay Evliyaoglu
Journal:  Pediatr Nephrol       Date:  2019-03-06       Impact factor: 3.714

7.  Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010.

Authors:  Hitoshi Sugiyama; Hitoshi Yokoyama; Hiroshi Sato; Takao Saito; Yukimasa Kohda; Shinichi Nishi; Kazuhiko Tsuruya; Hideyasu Kiyomoto; Hiroyuki Iida; Tamaki Sasaki; Makoto Higuchi; Motoshi Hattori; Kazumasa Oka; Shoji Kagami; Tetsuya Kawamura; Tetsuro Takeda; Hiroshi Hataya; Yuichiro Fukasawa; Atsushi Fukatsu; Kunio Morozumi; Norishige Yoshikawa; Akira Shimizu; Hiroshi Kitamura; Yukio Yuzawa; Seiichi Matsuo; Yutaka Kiyohara; Kensuke Joh; Michio Nagata; Takashi Taguchi; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2013-02-06       Impact factor: 2.801

8.  Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function.

Authors:  Yizhi Chen; Li Tang; Zhe Feng; Xueying Cao; Xuefeng Sun; Moyan Liu; Shuwen Liu; Xueguang Zhang; Ping Li; Ribao Wei; Qiang Qiu; Guangyan Cai; Xiangmei Chen
Journal:  J Nephrol       Date:  2014-02-13       Impact factor: 3.902

9.  Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.

Authors:  Choli Hartono; Miriam Chung; Sheng F Kuo; Surya V Seshan; Thangamani Muthukumar
Journal:  J Nephrol       Date:  2014-01-16       Impact factor: 3.902

10.  Membranous Nephropathy: Quantifying Remission Duration on Outcome.

Authors:  Daniel C Cattran; Esther D Kim; Heather Reich; Michelle Hladunewich; S Joseph Kim
Journal:  J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.